期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

甲状腺髓样癌的诊治 被引量：2

下载PDF
导出
摘要 甲状腺髓样癌（medullary thyroid cancer，MTC）是一种较少见的甲状腺恶性肿瘤．约占甲状腺恶性肿瘤的4％。MTC起源于甲状腺C细胞．即滤泡旁细胞．其中75％为散发性，25％为遗传性。绝大多数遗传性MTC为多发性内分泌瘤2型（mutiple endocfine neoplasm type 2。MEN-2）的相关病变。
作者 龚进发 陈曦
机构地区 上海交通大学医学院附属瑞金医院远洋分院外科 上海交通大学医学院附属瑞金医院外科
出处 《外科理论与实践》 2014年第3期195-200,共6页 Journal of Surgery Concepts & Practice
关键词 甲状腺髓样癌 全甲状腺切除术 综合治疗
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献45

  • 1Salehian B,Samoa R.RET gene abnormalities and thy-roid disease:who should be screened and when[J].J ClinRes Pediatr Endocrinol,2013,5(Suppl 1):70-78.
  • 2Blom CB,Ceolin L,Romitti M,et al.The rare intracellu-lar RET mutation p.Ser891 Ala in an apparently sporadicmedullary thyroid carcinoma:a case report and review ofthe literature[J].Arq Bras Endocrinol Metabol,2012,56(8):586-591.
  • 3Samulski TD,Livolsi VA,Montone K,et al.The variablepathologic presentations of medullary and micro-medullary thyroid carcinoma:an institutional experience[J].Pathol Res Pract,2014,210(3):182-185.
  • 4陈曦.甲状腺髓样癌诊治的若干问题[J].中国实用外科杂志,2011,31(5):398-401. 被引量：9
  • 5Machens A,Dralle H.Multiple endocrine neoplasia type2and the RET protooncogene:from bedside to bench tobedside[J].Mol Cell Endocrinol,2006,247(1-2):34-40.
  • 6Kazaure HS,Roman SA,Sosa JA.Medullary thyroid mi-crocarcinoma:a population-level analysis of 310 patients[J].Cancer,2012,118(3):620-627.
  • 7Costante G,Meringolo D,Durante C,et al.Predictivevalue of serum calcitonin levels for preoperative diagno-sis of medullary thyroid carcinoma in a cohort of 5817consecutive patients with thyroid nodules[J].J Clin En-docrinol Metab,2007,92(2):450-455.
  • 8Vainas I,Marthopoulos A,Chrisoulidou A,et al.Calci-tonin stimulation tests for the early diagnosis and follow-up of patients with C cell disease:a descriptive analysis[J].Hippokratia,2013,17(3):246-251.
  • 9Camacho CP,Lindsey SC,Melo MC,et al.Measurementof calcitonin and calcitonin gene-related peptide mRNArefines the management of patients with medullary thy-roid cancer and may replace calcitonin-stimulation tests[J].Thyroid,2013,23(3):308-316.
  • 10Chen H,Sippel RS,O' Dorisio MS,et al.The NorthAmerican Neuroendocrine Tumor Society consensusguideline for the diagnosis and management of uroen-docrine tumors:pheochromocytoma,paraganglioma,andmedullary thyroid cancer[J].Pancreas,2010,39(6):775-783.

二级参考文献14

  • 1Machens A, Dralle H. Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside[J]. Mol Cell Endoerinol,2006, 247 ( 1-2 ): 34-40.
  • 2Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules [J]. J Clin Endocrinol Metab,2007,92 (2): 450-455.
  • 3Herbert Chen, Rebecca S, Sue O' Dorisio SM, et al. The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer[J]. Pancreas,2010,39(6): 775-783.
  • 4Barber J, Campion L, Kraeber-Bodere F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma [J].J Clin Endocrinol Metab, 2005,90( 11 ): 6077-6084.
  • 5Roman S, Mehta P,Sosa JA. Medullary thyroid cancer: early detection and novel treatments [J ]. Curr Opin Oncol, 2009,21 (1) : 5-10.
  • 6Howe TC,Padhy AK, Loke K. et al. Role of Tc-99m DMSA (V) scanning and serum calcitonin monitoring in the management of medullary thyroid carcinoma [J]. Singapore Med J, 2008,49(1) : 19-22.
  • 7Kloos RT, Eng C, Evans DB, et al. Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association [J]. Thyroid,2009, 19(6):565-612.
  • 8Greenblatt DY, Elson D, Mack E, et al. Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer [ J ]. Asian J Surg,2007,30 ( 2 ): 108-112.
  • 9Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A [ J ]. N Engl J Med, 2005,353(11): 1105-1113.
  • 10Kebebew E, Greenspan FS, Clark OH, et al. Extent of disease and practice patterns for medullary thyroid cancer [J]. J Am Coll Surg,2005,200 (6): 890-896.

共引文献8

同被引文献31

  • 1李英淑,李立军.检测癌胚抗原对甲状腺癌的诊断意义[J].黑龙江医学,2005,29(3):170-171. 被引量：8
  • 2吕健东,张仑.70例甲状腺髓样癌治疗体会及预后分析[J].天津医药,2006,34(9):661-661. 被引量：2
  • 3金永锋.30例甲状腺髓样癌诊治分析[J].肿瘤学杂志,2007,13(2):134-135. 被引量：1
  • 4Cohen MS, MoleyJF. Surgical treatment of medullary thyroid carcinoma[J]. J Intern Med, 2003,253(6):616-626.
  • 5RomanS,MehtaSosaJA. Medullary thyroid cancer: early detection and novel treatment[J].Curr Opin Oneol, 2009,21(1):5-10.
  • 6Azar FKI, Lee SL, Rosen JE. Medullary thyroid cancer: an update for surgeons.[J].Am Surg. 2015,81( 1 ):1-8.
  • 7Freesmeyer M, Dralle H, Winkens T. Diagnosis of small medullary thyroid carcinoma via PET/ultrasound (US) fusion [J]. Jpn J Clin Oncol,2014,44(3 ):300-301.
  • 8Costante G, Meringolo D, Durante C, et al. Predictivevalue of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules[J]. J Clin En-doerinol Metab,2007.92(2):450-455.
  • 9Houvras Y.Completing the Arc: Targeted Inhibition of RET in Medul-lary Thyroid Cancer[J]. J Clin Oncol,2012,30( 2):200-202.
  • 10Kazaure HS, Roman SA, Sosa JA. Medullary thyroid microcarcinoma: a population-level analysis of 310 patients [ J ]. Cancer,2012,118 ( 3 ): 620-627.

引证文献2

外科理论与实践
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部